| Gene symbol | RRM2 | Synonyms | C2orf48, R2, RR2, RR2M | Type of gene | protein-coding |
| Chromosome | 2 | Map location | 2p25.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | ribonucleotide reductase regulatory subunit M2 | ||||
| GTO ID | GTC1293 |
| Trial ID | NCT00689065 |
| Disease | Cancer | Solid Tumor |
| Altered gene | RRM2 |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | CALAA-01 |
| Phase | Phase1 |
| Recruitment status | Terminated |
| Title | A Phase I, Dose-Escalating Study of the Safety of Intravenous CALAA-01 in Adults With Solid Tumors Refractory to Standard-of-Care Therapies |
| Year | 2008 |
| Country | United States |
| Company sponsor | Calando Pharmaceuticals |
| Other ID(s) | CALAA-01-ST-001 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||
|
|||||||